Abstract
Cutaneous nocardiosis is an infrequent infection which has been increasingly reported in immunocompromised patients. Although trimethoprim-sulfamethoxazole is considered to be the agent of choice for treatment of nocardiosis, newer antimicrobials such as tigecycline have been proven to be effective in vitro, as well. We report the first case of primary cutaneous nocardiosis in a renal transplant recipient having corresponded well to treatment with tigecycline.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / adverse effects
-
Kidney Transplantation / adverse effects*
-
Lymphatic Diseases / diagnosis
-
Lymphatic Diseases / drug therapy*
-
Lymphatic Diseases / immunology
-
Lymphatic Diseases / microbiology
-
Male
-
Middle Aged
-
Nocardia Infections / diagnosis
-
Nocardia Infections / drug therapy*
-
Nocardia Infections / immunology
-
Nocardia Infections / microbiology
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / drug therapy*
-
Opportunistic Infections / immunology
-
Opportunistic Infections / microbiology
-
Skin Diseases, Bacterial / diagnosis
-
Skin Diseases, Bacterial / drug therapy*
-
Skin Diseases, Bacterial / immunology
-
Skin Diseases, Bacterial / microbiology
-
Tigecycline / therapeutic use*
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Immunosuppressive Agents
-
Tigecycline